Meeting
2017 Genitourinary Cancers Symposium
Early toxicity in a prospective phase I/II trial of MRI-assisted focal boost integrated with HDR monotherapy for low- and intermediate-risk prostate cancer.
Authors
Laura D'alimonte
Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
Laura D'alimonte , Joelle Antoine Helou , Gerard Morton , Hans T. Chung , Merrylee McGuffin , Ananth Ravi , Andrew Loblaw
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Prostate Cancer,Urothelial Carcinoma,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Clinical Trial Registration Number
NCT02623933
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 120)
DOI
10.1200/JCO.2017.35.6_suppl.120
Abstract #
120
Poster Bd #
B14
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
5-Year result of single-institute cohort study in single-fraction HDR monotherapy for localised prostate cancer.
First Author: Imtiaz Ahmed
Poster
2016 Genitourinary Cancers Symposium
Early toxicity in a randomized trial of high dose-rate (HDR) brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.
First Author: Gerard Morton
Poster
2024 ASCO Genitourinary Cancers Symposium
The Capio Prostate Cancer Center model for prostate cancer diagnostics using Stockholm3, MRI, and targeted biopsies: Real-world evidence from 2018 to 2022.
First Author: Thorgerdur Palsdottir
Poster
2024 ASCO Genitourinary Cancers Symposium
Toxicity-benefit analysis of advanced prostate cancer trials using weighted toxicity scoring.
First Author: Jaspreet Kaur Gill